TCR SIGNALLING AND FYN SH3/SH2 INTERACTION
TCR 信号传导和 FYN SH3/SH2 相互作用
基本信息
- 批准号:2748770
- 负责人:
- 金额:$ 30.17万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1996
- 资助国家:美国
- 起止时间:1996-08-02 至 1999-07-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Tyrosine phosphorylation is the earliest and an obligatory step in T cell
activation. The Src family tyrosine kinases p59tyn (Fyn) and p56lck (Lck)
are critical for initiating tyrosine phosphorylation upon T cell receptor
(TCR) triggering. The basal repression and activation-dependent interaction
with signalling proteins require the Src homology (SH3 and SH2) domains of
Fyn and Lck. We have demonstrated a novel physical interaction between SH3
and SH2 domains of Fyn and Lck, which leads to the hypothesis that
repression of Fyn and Lck is mediated by dimerization. We have also
demonstrated a ligand-sensitive communication between adjacent Fyn SH3 and
SH2 domains, which we hypothesize to provide a mechanism to regulate
activation-dependent assembly of signalling complexes. Here, we will use
nondenaturing gel electrophoresis, density gradient centrifugation,
chemical cross-linking, two-epitope tagging and yeast two-hybrid
interaction to assess dimerization of Fyn and Lck in vivo, test if dimers
are modulated by T cell activation, and use deletional and mutational
analyses to assess that dimerization is mediated by SH3-SH2 interaction.
Full-length Fyn and Lck cDNAs, carrying mutations that influence the
physical and functional SH3-SH2 interactions, will be transfected into
cells to assess the in vivo biological functions of SH3-SH2 interactions.
Thus, we will assess kinase activity and transforming potential in
fibroblasts, enhancement of TCR signalling in Jurkat human T cells,
increase in antigen-responsiveness of two antigen-specific T cells,
association of mutant proteins with components of signal transduction
machinery, their subcellular localization and the status of the regulatory
interaction of SH2 with the C-terminal phosphotyrosine. Together, these
analyses should help establish the biological roles of the novel SH3-SH2
interactions in TCR signalling. If SH3-SH2 interaction-dependent
dimerization can be demonstrated, it will provide a new paradigm to
understand signalling through receptors that activate Src-family kinases.
Elucidation of the mechanisms of TCR signalling should facilitate analyses
of defective T cell immunity in AIDS and inappropriate T cell activation in
autoimmunity. Insights into regulation of Src-family tyrosine kinases may
also provide a better understanding of their oncogenic activation.
酪氨酸磷酸化是T细胞活化的最早和必不可少的步骤,
activation. Src家族酪氨酸激酶p59 tyn(Fyn)和p56 lck(Lck)
是启动T细胞受体酪氨酸磷酸化的关键
(TCR)触发。基础阻遏和激活依赖的相互作用
与信号蛋白的同源性需要Src同源性(SH 3和SH 2)结构域,
Fyn和Lck。我们已经证明了一种新的物理相互作用SH 3
和Fyn和Lck的SH 2结构域,这导致了以下假设,
Fyn和Lck的阻遏由二聚化介导。 我们还
证明了相邻的Fyn SH 3之间的配体敏感性通信,
SH 2结构域,我们假设它提供了一种调节
信号复合物的活化依赖性组装。在这里,我们将使用
非变性凝胶电泳,密度梯度离心,
化学交联、双表位标签和酵母双杂交
相互作用以评估体内Fyn和Lck的二聚化,测试是否为二聚体
受T细胞活化的调节,并使用缺失和突变
分析以评估二聚化由SH 3-SH 2相互作用介导。
全长Fyn和Lck cDNA,携带影响细胞增殖的突变,
物理和功能性SH 3-SH 2相互作用,将被转染到
细胞来评估SH 3-SH 2相互作用的体内生物学功能。
因此,我们将评估激酶活性和转化潜力,
成纤维细胞,增强Jurkat人T细胞中的TCR信号传导,
两种抗原特异性T细胞的抗原应答性增加,
突变蛋白与信号转导组分的关联
机制,它们的亚细胞定位和调节的状态,
SH 2与C-末端磷酸酪氨酸的相互作用。所有这些
分析应该有助于建立新的SH 3-SH 2的生物学作用,
TCR信号的相互作用。 如果SH 3-SH 2相互作用依赖
二聚化可以证明,它将提供一个新的范例,
理解通过激活Src家族激酶的受体的信号传导。
TCR信号传导机制的阐明将有助于分析
艾滋病中T细胞免疫缺陷和
自身免疫对Src家族酪氨酸激酶调节的认识可能
也提供了更好的了解他们的致癌激活。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hamid Band其他文献
Hamid Band的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Hamid Band', 18)}}的其他基金
Molecular Control of EGF Receptor Down-Regulation
EGF 受体下调的分子控制
- 批准号:
7909311 - 财政年份:2009
- 资助金额:
$ 30.17万 - 项目类别:
ErbB2 Downregulation Through HSP90 Inhibition
通过 HSP90 抑制下调 ErbB2
- 批准号:
8079123 - 财政年份:2007
- 资助金额:
$ 30.17万 - 项目类别:
ErbB2 Downregulation Through HSP90 Inhibition
通过 HSP90 抑制下调 ErbB2
- 批准号:
7212882 - 财政年份:2007
- 资助金额:
$ 30.17万 - 项目类别:
ErbB2 Downregulation Through HSP90 Inhibition
通过 HSP90 抑制下调 ErbB2
- 批准号:
7560152 - 财政年份:2007
- 资助金额:
$ 30.17万 - 项目类别:
ErbB2 Downregulation Through HSP90 Inhibition
通过 HSP90 抑制下调 ErbB2
- 批准号:
7632179 - 财政年份:2007
- 资助金额:
$ 30.17万 - 项目类别:
ErbB2 Downregulation Through HSP90 Inhibition
通过 HSP90 抑制下调 ErbB2
- 批准号:
7821323 - 财政年份:2007
- 资助金额:
$ 30.17万 - 项目类别:
ErbB2 Downregulation Through HSP90 Inhibition
通过 HSP90 抑制下调 ErbB2
- 批准号:
7477767 - 财政年份:2007
- 资助金额:
$ 30.17万 - 项目类别:
Endosomal ErbB Receptor and Src Signaling in Cancer
癌症中的内体 ErbB 受体和 Src 信号转导
- 批准号:
6916571 - 财政年份:2004
- 资助金额:
$ 30.17万 - 项目类别:
Endosomal ErbB Receptor and Src Signaling in Cancer
癌症中的内体 ErbB 受体和 Src 信号转导
- 批准号:
7227540 - 财政年份:2004
- 资助金额:
$ 30.17万 - 项目类别:
Endosomal ErbB Receptor and Src Signaling in Cancer
癌症中的内体 ErbB 受体和 Src 信号转导
- 批准号:
7555313 - 财政年份:2004
- 资助金额:
$ 30.17万 - 项目类别:
相似海外基金
Modulation of T lymphocyte Activation by Ã2-Adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
RGPIN-2019-06980 - 财政年份:2022
- 资助金额:
$ 30.17万 - 项目类别:
Discovery Grants Program - Individual
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
- 批准号:
10581488 - 财政年份:2022
- 资助金额:
$ 30.17万 - 项目类别:
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574979-2022 - 财政年份:2022
- 资助金额:
$ 30.17万 - 项目类别:
University Undergraduate Student Research Awards
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
- 批准号:
10332251 - 财政年份:2022
- 资助金额:
$ 30.17万 - 项目类别:
Modulation of T lymphocyte Activation by Ã2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574984-2022 - 财政年份:2022
- 资助金额:
$ 30.17万 - 项目类别:
University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574985-2022 - 财政年份:2022
- 资助金额:
$ 30.17万 - 项目类别:
University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by Ã2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574978-2022 - 财政年份:2022
- 资助金额:
$ 30.17万 - 项目类别:
University Undergraduate Student Research Awards
Investigating the cell-based activity of a new class of cytotoxic T-lymphocyte antigen-4 (CTLA-4) small molecule inhibitors
研究一类新型细胞毒性 T 淋巴细胞抗原 4 (CTLA-4) 小分子抑制剂的细胞活性
- 批准号:
444149 - 财政年份:2021
- 资助金额:
$ 30.17万 - 项目类别:
Operating Grants
Novel pathways in T lymphocyte differentiation and function
T 淋巴细胞分化和功能的新途径
- 批准号:
RGPIN-2015-05491 - 财政年份:2021
- 资助金额:
$ 30.17万 - 项目类别:
Discovery Grants Program - Individual
Modulation of T lymphocyte Activation by ß2-Adrenergic Receptor Signalling Pathways
通过 α2-肾上腺素能受体信号通路调节 T 淋巴细胞激活
- 批准号:
RGPIN-2019-06980 - 财政年份:2021
- 资助金额:
$ 30.17万 - 项目类别:
Discovery Grants Program - Individual














{{item.name}}会员




